問卷

TPIDB > Principal Investigator

Principal Investigator


CHANGHUA CHRISTIAN HOSPITAL (在職)

Digestive System Department

Division of Cardiovascular Diseases

Division of Endocrinology

Division of General Internal Medicine

Division of Endocrinology

更新時間:2023-09-19

蘇矢立
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

60Cases

2023-06-01 - 2026-12-31

Phase II

Active
A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults With Precirrhotic Nonalcoholic Steatohepatitis
  • Condition/Disease

    Non-alcoholic Fatty Liver Disease

  • Test Drug

    MK-6024

Participate Sites
7Sites

Recruiting7Sites

2023-07-01 - 2026-01-31

Phase III

Completed
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With Hypercholesterolemia
  • Condition/Disease

    Hypercholesterolemia、 Familial Hypercholesterolemia

  • Test Drug

    MK-0616

Participate Sites
7Sites

Recruiting7Sites

2024-05-01 - 2029-12-31

Phase III

Active
A Phase 3, Open-label Extension Study to Evaluate the Safety and Efficacy of MK-0616 in Adults With Hypercholesterolemia
  • Condition/Disease

    Hypercholesterolemia

  • Test Drug

    tablet

Participate Sites
10Sites

Recruiting10Sites

2009-04-01 - 2011-12-31

Phase II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2010-04-01 - 2011-06-30

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2023-06-16 - 2024-05-15

Phase III

Completed
A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1)
  • Condition/Disease

    Obesity、 Overweight、 Knee Pain Chronic、 Knee Osteoarthritis、 Obstructive Sleep Apnea

  • Test Drug

    LY3437943

Participate Sites
4Sites

Recruiting4Sites

2023-07-03 - 2028-07-26

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites